Judah Frommer
Stock Analyst
(3.11)
# 4,648
Out of 4,648 analysts
173
Total ratings
59.52%
Success rate
6.04%
Average return
Main Sectors:
Stocks Rated by Judah Frommer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCAX Bicara Therapeutics | Initiates: Overweight | $35 | $24.97 | +40.17% | 1 | Oct 8, 2024 | |
| GLPG Galapagos NV | Maintains: Equal-Weight | $38 | $26.71 | +42.27% | 2 | Apr 22, 2024 | |
| MURA Mural Oncology | Initiates: Overweight | $13 | $3.40 | +282.35% | 1 | Apr 4, 2024 | |
| PROK ProKidney | Assumes: Equal-Weight | $3 | $1.56 | +92.31% | 1 | Mar 7, 2024 | |
| ACLX Arcellx | Initiates: Overweight | $81 | $86.44 | -6.29% | 1 | Mar 7, 2024 | |
| JSPR Jasper Therapeutics | Reiterates: Outperform | $40 | $22.03 | +81.57% | 8 | Aug 14, 2023 | |
| ABOS Acumen Pharmaceuticals | Reiterates: Outperform | $13 | $2.95 | +340.68% | 5 | Aug 9, 2023 | |
| RNA Avidity Biosciences | Reiterates: Outperform | $30 | $44.82 | -33.07% | 8 | Aug 9, 2023 | |
| STOK Stoke Therapeutics | Reiterates: Outperform | $23 | $13.10 | +75.57% | 5 | Aug 8, 2023 | |
| PTCT PTC Therapeutics | Reiterates: Neutral | $50 | $40.39 | +23.79% | 9 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $141 | $123.07 | +14.57% | 13 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $1.72 | +655.81% | 5 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $9 | $1.08 | +733.33% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $18.03 | +22.02% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $7 | $5.19 | +34.87% | 3 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $8 | $3.26 | +145.40% | 5 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $15.55 | +195.82% | 5 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6.5 → $7 | $2.00 | +250.00% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $51 → $55 | $5.56 | +889.21% | 3 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $68.09 | -32.44% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $80.93 | -39.45% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $328 → $370 | $886.07 | -58.24% | 2 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $31 | $61.76 | -49.81% | 6 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $76 | $75.37 | +0.84% | 8 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $182 | $82.00 | +121.95% | 9 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $107 | $66.81 | +60.16% | 15 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $95 | $95.50 | -0.52% | 10 | Jul 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $18.45 | -2.44% | 1 | Jul 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $93 → $116 | $95.00 | +22.11% | 15 | Jun 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $86.75 | -56.20% | 4 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $22 | $131.79 | -83.31% | 1 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $35 | $56.27 | -37.80% | 9 | Apr 29, 2020 |
Bicara Therapeutics
Oct 8, 2024
Initiates: Overweight
Price Target: $35
Current: $24.97
Upside: +40.17%
Galapagos NV
Apr 22, 2024
Maintains: Equal-Weight
Price Target: $38
Current: $26.71
Upside: +42.27%
Mural Oncology
Apr 4, 2024
Initiates: Overweight
Price Target: $13
Current: $3.40
Upside: +282.35%
ProKidney
Mar 7, 2024
Assumes: Equal-Weight
Price Target: $3
Current: $1.56
Upside: +92.31%
Arcellx
Mar 7, 2024
Initiates: Overweight
Price Target: $81
Current: $86.44
Upside: -6.29%
Jasper Therapeutics
Aug 14, 2023
Reiterates: Outperform
Price Target: $40
Current: $22.03
Upside: +81.57%
Acumen Pharmaceuticals
Aug 9, 2023
Reiterates: Outperform
Price Target: $13
Current: $2.95
Upside: +340.68%
Avidity Biosciences
Aug 9, 2023
Reiterates: Outperform
Price Target: $30
Current: $44.82
Upside: -33.07%
Stoke Therapeutics
Aug 8, 2023
Reiterates: Outperform
Price Target: $23
Current: $13.10
Upside: +75.57%
PTC Therapeutics
Jul 20, 2023
Reiterates: Neutral
Price Target: $50
Current: $40.39
Upside: +23.79%
Jun 23, 2023
Reiterates: Neutral
Price Target: $141
Current: $123.07
Upside: +14.57%
May 16, 2023
Reiterates: Outperform
Price Target: $13
Current: $1.72
Upside: +655.81%
May 12, 2023
Reiterates: Outperform
Price Target: $9
Current: $1.08
Upside: +733.33%
Apr 3, 2023
Maintains: Outperform
Price Target: $21 → $22
Current: $18.03
Upside: +22.02%
Mar 31, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $5.19
Upside: +34.87%
Mar 10, 2023
Downgrades: Neutral
Price Target: $11 → $8
Current: $3.26
Upside: +145.40%
Mar 7, 2023
Reiterates: Outperform
Price Target: $46
Current: $15.55
Upside: +195.82%
Mar 7, 2023
Upgrades: Neutral
Price Target: $6.5 → $7
Current: $2.00
Upside: +250.00%
Feb 28, 2023
Maintains: Outperform
Price Target: $51 → $55
Current: $5.56
Upside: +889.21%
Feb 24, 2023
Reiterates: Outperform
Price Target: $46
Current: $68.09
Upside: -32.44%
Nov 5, 2020
Maintains: Outperform
Price Target: $47 → $49
Current: $80.93
Upside: -39.45%
Oct 6, 2020
Maintains: Neutral
Price Target: $328 → $370
Current: $886.07
Upside: -58.24%
Sep 21, 2020
Maintains: Outperform
Price Target: $24 → $31
Current: $61.76
Upside: -49.81%
Sep 21, 2020
Maintains: Outperform
Price Target: $65 → $76
Current: $75.37
Upside: +0.84%
Aug 6, 2020
Assumes: Neutral
Price Target: $182
Current: $82.00
Upside: +121.95%
Aug 6, 2020
Assumes: Outperform
Price Target: $107
Current: $66.81
Upside: +60.16%
Jul 22, 2020
Maintains: Neutral
Price Target: $90 → $95
Current: $95.50
Upside: -0.52%
Jul 21, 2020
Initiates: Outperform
Price Target: $18
Current: $18.45
Upside: -2.44%
Jun 10, 2020
Maintains: Outperform
Price Target: $93 → $116
Current: $95.00
Upside: +22.11%
May 22, 2020
Maintains: Outperform
Price Target: $31 → $38
Current: $86.75
Upside: -56.20%
May 6, 2020
Maintains: Neutral
Price Target: $18 → $22
Current: $131.79
Upside: -83.31%
Apr 29, 2020
Maintains: Neutral
Price Target: $33 → $35
Current: $56.27
Upside: -37.80%